Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Up 5.88%
As of Monday, November 09, Nurix Therapeutics, Inc.’s NRIX share price has surged by 5.88%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Tudor Pop
Jenna Brashear
| Share Statistics | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,403.3 | $203.5 | 51% |
|
| Shares Out (Mil) | 116.2 | 55.2 | 65% |
|
| Institutional Ownership | 99.0% | 93.3% | 83% |
|
| Float (Mil) | 87.2 | 40.4 | 57% |
|
| Beta | 1.82 | 1.05 | 89% |
|
| Avg Daily Volume (000s) | 2,821 | 569 | 86% |
|
| Price Change (52-week) |
(10.4%) | 38.8% | 45% |
|
| Growth | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.4% | 13.6% | 92% |
|
| Net Income (5yr) | (43.7%) | (10.7%) | 8% |
|
| EPS (5yr) | (2.0%) | 15.4% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (21.8%) | (15.7%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $1.508 | $3.021 | ($1.276) | |
| Month Ago EPS | $1.508 | $3.021 | ($1.276) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 3 | 1 | 0 | |
| Three Months Ago EPS | ($0.369) | $1.787 | ($1.439) | |
| Year/Year Chg | (68.1%) | (199.0%) | (85.2%) | |
| Financials | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $702 | $40 | 45% |
|
| Net Income (TTM) (Mil) | $295 | ($44) | 72% |
|
| EPS (TTM) | $2.757 | ($1.400) | 76% |
|
| Operating Cash Flow (TTM) (Mil) | $379 | ($35) | 67% |
|
| Net Cash Flow (TTM) (Mil) | $642 | $-0 | 92% |
|
| Long-Term Debt (Q1) (Mil) | $62 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $1,603 | $142 | 47% |
|
| Valuation | NRIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.45 | 1.96 | 46% |
|
| P/E | 4.8 | 16.9 | 5% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.4% | 67.6% | 64% |
|
| Net Margin | 42.0% | (50.8%) | 95% |
|
| ROA | 34.3% | (47.0%) | 99% |
|
| ROE | 44.0% | (51.8%) | 92% |
|
| Liabilities to Assets | 19.0% | 29.6% | 12% |
|
| F-Score | 7 | 3 | 82% |
|
Passing Stock Screens
As of 11/20/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.7 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors